Product image of Linagliptina Pharmapath (Linagliptin) supplied by GNH India

Linagliptina Pharmapath

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptina Pharmapath (Linagliptin)

Linagliptin, the active ingredient in Linagliptina Pharmapath, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used as part of a comprehensive diabetes treatment plan.

GNH India supplies Linagliptina Pharmapath as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements to ensure product integrity across global markets.

Manufacturer / TM Owner

Towa Pharmaceutical S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

  • Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels when used alone.
  • Type 2 diabetes mellitus (combination therapy): enhances glycaemic control when added to metformin or other oral antidiabetics.
  • Type 2 diabetes mellitus (post‑prandial control): reduces post‑prandial glucose excursions as part of a diet‑and‑exercise regimen.

How It Works

  • Linagliptin reversibly inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which degrades the incretin hormones GLP‑1 and GIP. By preventing this degradation, endogenous GLP‑1 and GIP levels rise, leading to glucose‑dependent stimulation of insulin secretion and suppression of glucagon release, thereby improving post‑prandial and overall glycaemic control.

Side Effects

Common Side Effects

  • Nasopharyngitis: mild inflammation of the nasal passages and throat.
  • Headache: transient head pain of varying intensity.
  • Upper respiratory tract infection: symptoms such as cough, sore throat, or congestion.
  • Dizziness: brief episodes of light‑headedness.
  • Gastrointestinal discomfort: mild nausea or abdominal pain.
  • Back pain: occasional musculoskeletal discomfort.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain with possible vomiting, requiring immediate medical attention.
  • Severe allergic reactions: rash, swelling, or difficulty breathing.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Hypersensitivity reactions: including angioedema.
  • Severe joint pain: unexplained arthralgia.
  • Bullous skin reactions: blistering skin conditions.

Precautions & Warnings

Linagliptina Pharmapath should be used with clinical judgment and patient monitoring.

  • Renal impairment: assess renal function; dose adjustment may be required.
  • Hepatic impairment: monitor liver enzymes during therapy.
  • Cardiovascular disease: use with caution in patients with existing heart conditions.
  • Elderly patients: observe for signs of hypoglycaemia when combined with insulin or sulfonylureas.
  • Drug interactions: review all concomitant medications for potential interactions.
  • Store at room temperature: keep in the original packaging, protect from moisture and light.

Avoid Interactions

Linagliptina Pharmapath may interact with other medicines; monitoring is advised.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors: may increase linagliptin exposure and risk of adverse effects.
  • Insulin or sulfonylureas: combined use can raise the risk of hypoglycaemia.

Moderate Interactions (Monitor Closely)

  • Rifampin: may reduce linagliptin effectiveness.
  • Diuretics: may influence glucose control.
  • ACE inhibitors: monitor renal function and blood pressure.

Frequently Asked Questions

Linagliptina Pharmapath contains linagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus in adults. It helps improve blood glucose control when used as part of a comprehensive diabetes management plan that includes diet and exercise.

Linagliptin blocks the enzyme dipeptidyl peptidase‑4, which normally breaks down the incretin hormones GLP‑1 and GIP. By inhibiting DPP‑4, linagliptin raises endogenous incretin levels, leading to glucose‑dependent insulin release and reduced glucagon secretion, thereby lowering blood glucose.

The prescribed dose of Linagliptina Pharmapath is determined by the treating healthcare professional based on the individual patient's clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety of linagliptin in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin is distinguished by its high binding affinity and a long half‑life that allows once‑daily dosing without dose adjustment in mild to moderate renal impairment, whereas some other DPP‑4 inhibitors require renal dose modifications.

Store Linagliptina Pharmapath at room temperature, below 25 °C, in the original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain product stability.

Linagliptina Pharmapath is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with water and not crushed or chewed.

Serious risks include pancreatitis, severe allergic reactions such as angioedema, and rare hepatic injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or signs of liver dysfunction.

Linagliptina Pharmapath is contraindicated in patients with a known hypersensitivity to linagliptin or any of the tablet’s excipients. Caution is also advised for individuals with a history of pancreatitis or severe hepatic disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT